Serious investment thinking that doesn’t take itself too seriously.

HOME

LOGIN

ABOUT THE CURIOUS INVESTOR GROUP

SUBSCRIBE

SIGN UP TO THE WEEKLY

PARTNERS

TESTIMONIALS

CONTRIBUTORS

CONTACT US

MAGAZINE ARCHIVE

PRIVACY POLICY

SEARCH

-- CATEGORIES --

GREEN CHRONICLE

PODCASTS

THE AGENT

ALTERNATIVE ASSETS

THE ANALYST

THE ARCHITECT

ASTROPHYSIST

THE AUCTIONEER

THE ECONOMIST

EDITORIAL NOTES

FACE TO FACE

THE FARMER

THE FUND MANAGER

THE GUEST ESSAY

THE HEAD HUNTER

HEAD OF RESEARCH

THE HISTORIAN

INVESTORS NOTEBOOK

THE MACRO VIEW

POLITICAL INSIDER

THE PROFESSOR

PROP NOTES

RESIDENTIAL INVESTOR

TECHNOLOGY

UNCORKED

More poison from Twitter

by | Apr 20, 2022

Investor’s Notebook

More poison from Twitter

by | Apr 20, 2022

In response to Elon Musk’s all-cash takeover offer for Twitter, its board of directors has adopted a one-year shareholder rights plan to stop it. As Lucas Manfredi reported for FOX Business, the board claimed the plan “is intended to enable all shareholders to realise the full value of their investment in Twitter” and “reduce the likelihood that any entity, person or group gains control of Twitter through open market accumulation without paying all shareholders an appropriate control premium or without providing the Board sufficient time to make informed judgments and take actions that are in the best interests of shareholders.”

The so-called shareholder right’s plan would be implemented “if an entity, person or group acquires beneficial ownership of 15% or more of Twitter’s outstanding common stock in a transaction not approved by the board”, allowing the other shareholders to buy additional shares of common stock at half the current price, which is a ‘free money’ proposition for them. 

In other words, Twitter’s board was claiming to impose the plan to protect their shareholders. If that were true, and they were giving away wealth to them, Twitter stock should have skyrocketed at the news, but with the announcement coming on Good Friday, when the markets were closed, such a clear signal is not available. By Monday, when the market reopens, other new information will have contaminated the signal. But if it is of any use as a guide, the language Twitter’s board used for their poison pill was nearly a paraphrase of the language used by Yahoo!’s poison pill in 2001 (“designed to deter coercive takeover tactics, including the accumulation of shares in the open market or through private transactions, and to prevent an acquirer from gaining control of Yahoo! without offering a fair and adequate price and terms to all of Yahoo!’s stockholders”) and Yahoo! stock fell 11% the next day.

Why would stockholders react less than enthusiastically to something called a “shareholder rights plan”? Why would they dislike being given stock worth twice what they paid? The more common term for such plans, ‘poison pills’, points us to the reason.

“n attempted takeover by someone not friendly with existing management is a ploy to stop a takeover attempt”

On the surface, such plans seem to clearly benefit current stockholders., but in fact they often harm them. The dilution of share value that would result from other owners buying more shares at a discount after an attempted takeover by someone not friendly with existing management is a ploy to stop a takeover attempt. And a simple numerical example illustrates why. Suppose a takeover could generate added wealth of $2bn in an enterprise under new management. But when it is attempted, it triggers a giveaway of $3bn to other shareholders. That prospect means it is no longer worth trying to take over the firm, despite being a way to create billions of dollars in value.

In other words, when a firm’s management fails to maximise shareholder value, a takeover or merger can install new management that promises to perform better. Such takeovers pay shareholders a substantial premium over current share prices (nearly 40% in the case of Musk’s offer for Twitter), a premium they would very much like to receive. But a poison pill can prevent such a restructuring and protect the current management and board from the threat of being ousted. And poison pills are the most effective takeover defense allowed by the courts without shareholder approval (If they were subject to shareholder approval, owners could defend themselves against harm by voting them down.) Since, as Columbia University law professor John Coffee notes, “no court has overturned a poison pill in the last 30 years”, that has made it the go-to strategy in such cases. As a result, despite the uniformly pro-shareholder rhetoric that accompanies poison-pill announcements, in fact they are often devices to benefit existing management and shortchange shareholders.

Courts have permitted poison pills in deference to the ‘business judgment’ rule, which presumes that boards of directors act in the interests of their shareholders rather than to preserve the managers’ interests or their own positions on the board. But this is misguided in the case of unapproved poison pills. Allowing the management and board, which are delegated agents of stockholders, the right to preserve their jobs by halting takeovers that owners could decide to accept or reject for themselves effectively gives those bodies the right to change their employment contract unilaterally so that owners can no longer fire them in favour of another management team. Shareholders would never agree to a delegation of power to management that is so clearly contrary to their interests, which is why shareholder activists often oppose poison pills.

“Poison pills can really be nothing-for-something deals”

This lays the blame for the abuse of poison pills squarely on the courts’ historical misunderstanding of shareholders’ interests. They have essentially viewed poison pills as something-for-nothing deals for current shareholders, and since (in their view) shareholders would never oppose such a free lunch, their permission is not required before management unilaterally adopts them. However, as illustrated in our numerical example, poison pills can really be nothing-for-something deals that current shareholders would reject, given the chance. 

The supposed additional shareholder rights granted by poison pills are nearly valueless, as their mere existence typically undermines or eliminates takeover attempts that would trigger them. But they do take from shareholders not on the board the right to the premium prices they could have received if a hostile takeover had remained possible. Taking away this valuable shareholder option without their consent is not in owners’ interests, as commonly reflected by negative stock price changes when poison pills are adopted without shareholder approval.

It is hard to see how Twitter’s board is really trying to protect stockholders from abuses to their rights when a takeover offer would provide a hefty premium to all shareholders. However, their actions do seem consistent with extracting more for themselves at stockholders’ expense by denying them the choice. And there are far less restrictive ways to protect stockholders from any potential abuse, such as requiring that any offer for shares must remain in place for a period long enough to give other bidders a chance to counter with an even higher offer that would benefit current owners more. But such alternatives were not apparently considered.

In the words of financial economists Andre Shleifer and Robert Vishny, “hostile takeovers are probably the most effective way for shareholders to get rid of non-value-maximising managers”. Unilateral board adoption of poison pills short circuits that mechanism. Given that there are alternative ways to protect stockholders from any abusive takeover tactics, poison pills are more likely a defense of bad management than a defense of stockholders rights. They undermine the market for corporate control and, as a result, the value of stockholders’ investments. And when boards claim that they are necessary to act “in the best interests of shareholders” by taking the choices out of shareholders’ hands, it reveals far more about hypocrisy than the truth. 

Originally published by The American Institute for Economic Research and reprinted here with permission.

About Gary M Galles

About Gary M Galles

Dr Gary Galles is a Professor of Economics at Pepperdine. His research focuses on public finance, public choice, the theory of the firm, the organisation of industry and the role of liberty, including the views of many classical liberals and America’s founders­.His books include Pathways to Policy Failure, Faulty Premises, Faulty Policies, Apostle of Peace, and Lines of Liberty.

INVESTOR'S NOTEBOOK

Smart people from around the world share their thoughts

READ MORE >

THE MACRO VIEW

Recent financial news and how it connects across all asset classes

READ MORE >

TECHNOLOGY

Fintech, proptech and what it all means

READ MORE >

PODCASTS

Engaging conversations with strategic thinkers

READ MORE >

THE ARCHITECT

Some of the profession’s best minds

READ MORE >

RESIDENTIAL ADVISOR

Making money from residential property investment

READ MORE >

THE PROFESSOR

Analysis and opinion from the academic sphere

READ MORE >

FACE-TO-FACE

In-depth interviews with leading figures in the real estate/investment world.

READ MORE >